The Truth About Aging: Longevity Expert Debunks Common Misconceptions w/ Jamie Justice | EP#75

28:14I'm just so happy that you built this Yeah, well, so the very first competition conversation conversation I had was after the space flight prize some 15 years ago was a conversation with with Aubrey DeGrey and Peter Teal and it was right in the longevity prize So we couldn't figure out what the price would look like if we had to wait 30 years for it to be awarded or 20 years for to be awarded So it was difficult Five years ago, a gentleman named of Sergei Young Who is a partner with me in my bold longevity venture fund and super proud of what Sergei's built He put up a half million dollars to try and kick off this idea of a of a longevity prize again and that was the money we used to sort of design and develop the prize.

29:03And it was a conversation with George Church at Harvard Medical School, who's one of the most prolific and entrepreneurial, you know, biotech faculty out there. He's amazing. And he said, rather than longevity, what you really have to look at is functional reversal, because I don't care what your age in clock says. If you feel better, if your systems are working better, you can measure that in the now, and they're probably FDA -approved endpoints. And so we said, a true aging therapeutic, if it works in one system, it's likely to work in others. So let's look at three. And I met a guy named Chip Wilson.

29:50and many may know Chip's company. It's called Lululemon. He founded it, amazing entrepreneur and philanthropist. And Chip has this muscular dystrophy, FSHD. And he became the first major sponsor of this prize. He put up a quarter of the prize money and a $10 million bonus if your therapeutic can impact muscle and help his particular disease. So we have $101 million for the health span, ex -price health span, and 10 million for this FSHD bonus prize, this muscular dystrophy bonus prize. And so we set muscle as one. And one of the biggest issues around aging is sarcopenia, the loss of muscle. And a lot of people, my dad included, fell in his mid -80s, broke his hip that put him into the hospital, develop pneumonia and then passed away and we see this over and over again if you Have muscle wasting and you trip while walking and you break a hip or pelvis It really is the beginning of the end.

31:03It's really Challenging so how do you maintain muscle function was one of the biggest things? Where do you want to go next you want to go to immune or cognition? Yeah, I want to I want to sort of follow that thought that I think that's really great So actually that's my intro to aging was exactly around that So I started looking at the neuromuscular determinants of functional decline. And that was my graduate work and then followed that into more systemic sort of multifunction and really focused on physical dysfunction, frailty, disability. And know that those are really incredible drivers and those are some of the things that are so meaningful to people.

31:39So we can do a deep dive in some of these others. One thing I want our audience to know, especially the team's out there, which I really hope you compete, I will track you down. So, again, so when we're talking about muscle, this is function, but it's also it's not single dimension, right? And so we're talking about it can be, muscle is kind of broad, so it also means like fitness. So, you know, whether that is going to be like a cardiopulmonary kind of thing, like a VO2 max, or could be like a six minute walk, something like that that requires that you have to move, you have to walk, it requires endurance.

32:18We're also looking at strength and power, as well as that muscle mass component. So again, we're looking at multiple measures of this, so you can't just get one measure and call it good. We're making this hard, okay guys? So we are putting out and you should link to it on the website is you'll go in there. There's going to be a competition guideline. That's an initial guideline set, but you can link into it and you can see a menu of suggested tests that we're going to be refining with your input. So please join us in this. So again, muscle physical function is so important. We'll put the link into the show notes and again, xprice .org or xprice .org slash Hellspan.

33:02And I think you made an important point. When we launch an X Prize, we announce it with a set of guidelines versus the final rules. And we've had a six -month period where the world gives you feedback. I'm so happy to have you. I get to draw the arrows and the bring him my way guys. Radically collared. Yes, it's not me getting the feedback it's you as the executive director. And you have an amazing endpoints committee who are guiding you here. And so then we'll refine it, get the feedback, what do we miss, what do we get right, what do we get wrong, and then we'll announce the final rule set that will guide the agreements we have with the teams.

33:50So that's muscle. You know, everybody who's getting older, I think their biggest fear is cognition. It's losing their mind more than anything else. Yeah, so I think this is actually the perfect segue. So the three systems, one of the reasons that I was really excited and really made the move to X -Prize and delete this prize is because it was function -forward. And that it's you captured the essence of aging, meaning that it's not one system. And then I think by making this based on function rather than disease, it really gets to the heart of what health is. Health is more than the absence of disease.

34:29And so we're taking this very holistic look where we're looking at physical function, what we're calling muscle, right? We're also looking at cognitive function because as Peter said, like the things that worry us and actually lead to disability, these are sort of the three horsemen, right? is that inability to physically participate in our life. An ability to mentally participate in our life, whether that's memory, there's also something we call executive functioning. So that's like, can I keep track of multiple things at the same time? Not just what my memory goes, which we think about with Alzheimer's.

35:03But there's also many, many other components of this, whether it's a general slowing or just a gap or where I can't do two things at the same time anymore. And so these are some of those really core functions that are really essential in participating in life. And then the third, I don't think I need to tell anybody in the world right now after going through an internet pandemic, how important our immune function is. Is it one of the things we learn through pandemic where our older adults, those over the age of 60 and 65, or people that had something like comorbidity to where he had some kind of a chronic illness, which is much more frequent in older adults, is that those were the ones that were preferentially targeted by this pandemic.

35:51And so, you know, what we've really started learning is that we need to do what's called host directed therapies to improve our immune systems. Again, if we target that aging biology, we can improve our immune function and become more resilient in the face of many different challenges, including the next pandemic, whatever it is. And so these are the three most critical pillars, and they're not independently tied to any single disease. So what we're talking about is aging, what we're talking about is health, and that we're developing therapies of any kind. And it can't be just one. It has to be all three, so that we're sure we're not just going after a single problem.

36:29Yeah, beautiful. You said, Jamie, also remember remind us that your immune system is not just for an infectious disease. Your immune system protects you against cancer as well. That's exactly right. That's exactly right. We're all developing cancer all the time. It's just normally our immune system finds it early and zaps it. And if your immune system weakens or if you have immune exhaustion as they call, it increases the rate of cancer. Yep. I want to emphasize one other part with this. I think it's super, super critical. Is that these three really go together and they get at something, we haven't talked about the economic impacts yet.

37:12I think that's really important. When we think about aging, we often, I think there may be a misperception with this prize. It's like, oh, we're going to launch this prize and we only want rich people to live longer and that they're going to have this huge divide. By setting the price up this way and looking at function, what we're really going after is population level change, right? So right now in the US, for every 10 % increase in the fraction of the population over the age of 60, it actually the GDP, the gross domestic product, that it actually goes down just under 6%. And so in the next years, we're actually already had an increase of more than that.

38:03And so we're looking at really major changes and what they think most of that loss of GDP is due to is actually, it's a loss of labor supply. And so we're looking at things that can possibly impact function. We're talking about these are the things that could actually keep people active in their communities, whether or not they're working in sort of a for -profit position or staying at a job per se, but they're still participating. They're still able to take care of their kids, their grandkids, they're working, they're doing something because it's not just whether that individual stays in the labor pool working, but it also means that they're less dependent on a caregiver who might have to leave work to take care of them, a family member, a child, and niece and nephew.

38:50And so this is really critically important is that these are the things that will improve function and keep people engaged, active, healthy, participating. That's the goal. Absolutely. The numbers, I guess it was, you know, the publication here, David Suclair is one of the co -authors, and it was also was supported by Oxford and Harvard here that adding just one year to the global life expectancy on the average is worth $38 trillion to the global economy. And it's like in less, you know, both increased productivity and also decreased spending on medical health. Yeah. I mean, it's a massive, massive impact.

39:34And I think one of the things that is true for this prize and true for all exprises is is it's around equitable impact globally. Our hope is, and the structure of the competition, is that these therapeutics are not gonna be, you know, million dollar treatments, eventually, as you offer these treatments to millions, hundreds of millions and billions of people, the price comes down massively and becomes available. and what we truly want is increasing global health span. You know, there's a lot of people who argue, and I just want to get to the heart of this one second, let's say, oh my god, we already have too many people on the planet.

40:23You know, we have overpopulation issues. Why do you want to have people live longer? There's a lot of people, and we can talk about these individually. But I wanted to talk about the pro and the con for a second and then come back to the rules here. I mean, I'll just mention off the bat, increasing health span is about keeping people in the game longer. People retire either because they're in pain, they're tired or they're forced by policy to get out. But imagine at 65 if you are vibrant, you have the most context ever, you're excited to contribute and excited to start your next startup or do whatever you want.

41:07It is a huge positive impact on society. And people who are concerned about population, let me just give the stats because I know these numbers well. Well, 50 years ago, the average globally, number of children per family was over 5 children per family. It was like 5 .4. The replacement number is 2 .1. 2 .1 children per family is the average to keep the population level. We've gone from like 5 .4 down to 2 .3 right now. And most of the world, China, Japan, most of Europe, the United States is below the replacement level. And so, you know, we're possibly going to have one of the world's, you know, a problem on the flip side, not enough labor to sustain our global economy.

41:57Actually, that's correct. That's one of the biggest concerns. And so, you know, the U .S. certainly were on that trajectory. Other countries are already grappling with it. You know, Japan, many other countries where it's, you know, they have had major demographic changes. And so that's why, you know, globally, both the UN and the World Health Organization, they have named this the decade of healthy aging. And it's exactly for this reason is that there are many countries right now that don't have the labor needed, the people within that labor supply to support the number of persons who are actually retired and needing care and support.

42:34It's already happening. And this isn't just for, you know, really wealthy countries already. The countries that are actually going to see the most change and the next say 10, 20, 30 years. Those are our lower and middle income countries. We need solutions now that are available to support this really major global demographic shift. We've already seen some of it in our country. Other countries are just coming on board. We have changed what human aging looks like and we need to change it more so that we have support available and options available. Let me ask you who can compete for this ex prize?

43:12Who can register as a team? Anyone, anyone, anyone. I want people from everywhere jumping in this. This is a great opportunity. I mean, it could be from our nonprofit foundations, academic and investigators from any country. It could also be commercial for profit companies. So this could be somebody in the biotech space that might already actively be working on therapeutics that think would actually help and benefit aging. This could be from groups working in other disease categories. I know of some folks that working in cancer oncology that may have some things that could be repurposed or reconsexualized toward aging.

43:56There are also some active companies and also academic teams that have been working on pieces, as you know in the US, there's been a huge, huge increase in the amount spent for research on Alzheimer's disease, trying to find a cure, trying to find a treatment, is that there may be opportunities there that maybe some of those drugs, some of those compounds, might have effects well beyond cognition, and they just need the incentive to actually try them, because we need options for aging more holistically, and this is a chance to do that. So again, we expect anybody, the important part of X -Prize, one of the things that brought me here.

44:34And I think it's so central to ex -prises mission and it's really dear to my heart is decentralized. The next great idea could come from anyone. Yes, I love that. I love that. You know, one thing that's important to point out for those is ex -prise makes no claim on a team's intellectual property. This is a non -delutive capital that a team gets. Our job is simply to support, promote, help, hopefully hundreds of teams get attention and hopefully as part of this, just like we did with the original Spaceflight XPRIZE, and we've done with other XPRIZE's, also pave the regulatory path. So work with, in this case, the FDA and regulators around the world to be supportive of the kinds of strategies and approaches that are coming here.

45:27So that's a really great thing. And so these two actually go hand in hand. So when I just mentioned a little bit ago that we invite anyone, maybe biotech companies groups that are out there that are already working in this space, maybe they're developing things around aging. So I'm going to tell you something crazy, Peter. So there are some companies that have been working on aging, developing therapeutics around aging. And I talked to one of them recently and I was like, well, what would you think? Would you think about competing in this prize? I did this a few months ago before they had an opportunity to start really letting this digest.

46:00And one of their founding CEOs said, no, because there's no commercial incentive for us to actually do anything towards aging, because there's no regulatory pathway. There's nothing there. So we'll just keep developing our drugs and working on them in this rare disease, that rare disease, this rare disease. because even though they were at their heart targeting the biology of aging, they saw this as a full -scale game. Because there's no one here being the champion to bring everyone together to force or you know, and it's not really forcing the FDA, they're receptive, they want to help, but they need us to bring it to them.

46:39And it's too large of a challenge for any one company or any one academic group to do it on their own. And so again, And this could be for anyone anywhere. And the goal is to link these groups together, develop common resources, and actually work together, create change. This is a radically collaborative effort. We're putting out an initial guideline. We're telling you what we think, and we're asking for input. Everybody gets to be part of this with us. We are democratizing science in the field of aging. Just to remind people, you read about SpaceX and Blue Origin and relativity space now and Virgin Galactic and all of these companies and you say you think about commercial spaceflight and commercial human spaceflight as an everyday activity and you can go and buy a ticket right now.

47:25When the X Prize originally got thought up in 94 and announced in May of 1996 that was not the case by any means. The regulations didn't exist, people were not investing in this. It was before all of these companies got started and the X Prize really lit the views on commercial space and made it a much more rational investment and created the regulatory framework that has launched this commercial spaceflight. And we want to do the same thing here in the field of health, span, extension. There's a hundred, well, you know, I'm very proud to have raised $141 million for this competition. It's the largest amount of capital ever raised for an ex -price, yay?

48:09Wow, Peter, that's incredible. And I believe enough in this that I've put in millions personally into this competition, the first exprise I've backed. And as I mentioned, Chip Wilson was our largest first prize sponsor, and then we've had people putting in a million bucks, up to 40 million bucks, and it's our largest group here. Let's talk about how this money gets distributed. 30 million is for operations. There's a lot of testing has to be done. 10 million is up for this FSHD prize. Small pitch there. 30 million for operations. I might sound like a lot. This is a lot to run. And so any of our partners out there, if anyone's out there, maybe you've got a great idea, great biomarker, great system, something you want to ask us about.

49:00We're not closed. Feel free to call us for in -con support. Yeah, we're going to be partnering with companies to do testing in the cognition, immune, and muscle space, and a whole bunch of biometric testing along the way. And we'll be announcing partners in epigenetic testing and genome testing and blood biomarker testing and so forth. And this is a global competition, so we're going to have to be doing this around the world. But there's 101 million up for grabs for the primary segment of this prize. And unlike winner take all, which we have done in the past, we're doing this a little bit differently.

49:47I'm excited about it. Would you lay out how that 101 million is there for teams to go after? Okay, so this is great. So again, we have 101 million. This is one of the most common questions that I've had since we've launched Peter. Is people want to know, are we just giving? Is it a winner take all? Is it a one prize, one shot? And no, because that's really not the spirit, right? That this is meant to get people in the field and keep them there. And so I think one of the brilliant things that Peter and some of the early developers on this is to find a way to distribute this money. And so again, it is a competition.

50:25And so this requires that you have to come into this with some funding on your own to do the earliest stage. Those first two years, that's going to be a lot of qualifying submissions. You have to turn in paperwork to us. We have to understand the therapeutics that you're working with in the screening process that you have. And we'll do some evaluating based on that. At that point, it's going to be in the early, about right around two year mark for us, which is going to be in early 2025. will look at those qualifying submissions and there's going to be the first $10 million distribution. That awarding is going to go to 40 teams will be given some money that 10 million will be distributed.

51:11So that's about $250 ,000 a team and we know that you know depending on where you're testing from that may or may not be a lot for you but we wanted to make sure that we at least distributed money to encourage people keep them going, keep them invested in this, and it's a token to keep moving. More teams than 40 can continue, but we're only doing the awarding at that point. And another about year and a half ish after that point into 2026, we're going to be distributing again that next milestone award. At this point, teams will have had to go in to do at least some early clinical trials work. And so this is making sure that they can use the protocols that we're going to recommend, are comfortable and have the regulatory paperwork necessary, and a clinical trial center that they can support their work.

52:01Or we can help partner them with network, with folks within our alumni and team network that can help them along the way. And so then that's that next $10 million distribution. So again, now we've given away $20 million. that next 10 million is given to 10 teams. Those 10 teams will use that $1 million each to at least see their one -year clinical trial. The clinical trials were one and again we're going to be asking these teams. They're going to be testing function. That's muscle, cognitive and immune function. We need them at the beginning. At baseline they'll give whatever that therapeutic intervention, and whatever their team solution is.

52:43One year later, those clinical trials are run again. You have to test those same things again, muscle, cognitive, and immune function. We take that in also with some of the safety data that you collect, you know, any kind of event reporting or symptoms, we'll look at dropouts or adherents or anything that's related to that that will support the awarding. But our awarding is based on change in function and that you have to show a functional improvement. And we break down that 101, which remaining at this point is 81, because we've given away 20. Now we have the 81. If you can show that the improvements in function in one year are enough to offset that's equivalent to a 10 year, or decline, it's enough to offset the 10 year declines.

53:31You have to have an improvement in magnitude. This is equivalent to 10 year. That is, well, the team will be awarded 61 million. If you can show a 15 -year functional improvement, that's 71 million. If you can show, again, this is Peter's. So I thought 10 -year three systems was the most insane thing I could think of. Peter is exponential. And so this is the exponential goal for 81 million is that you have to show a 20 -year, the equivalent of a 20 -year improvement in all three systems for 81 million. And just to be clear, the highest level wins the money. So if you showed 10, but someone showed 15, the team who got 15 wins it.

54:20And this competition is going to run for seven years from launch at the end of seven years is hopefully we have a winner by that point. That's exactly right. And so, yeah, 2030 is that our goal period. And so, this gives our teams actually in having that amount of time. Yes, it takes time to run trials. The other thing, it takes time to get the regulatory paper work done and make sure that you have the resources and the network building and that we can actually begin to work and lay that ground work around what is possible for the future. And so, that's why we have this duration, is it just takes time to run these trials and it takes time to build the community in late.

55:03What we want to make this again, it's not meant to be a prize, a one and done, we give the money away and everyone goes home. Is that this is meant to make global lasting change. We're about an impact. Over the years, I've experimented with many intermittent fasting programs. The truth is, I've given up on intermittent fasting as I've seen no real benefit when it comes to longevity. But this changed when I discovered something called Prolon's 5 -day fasting and nutrition program. In harnesses the process of autophagy. This is a cellular recycling process that revitalizes your body at a molecular level.

55:40And just one cycle of the 5 -day Prolon fasting nutrition program can support healthy aging, fat -focused weight loss, improved energy levels and more. It's a painless process and I've been doing it twice a year for the last year. You can get a 15 % off on your order when you go to my special URL. Go to prolonlife .com, P -R -O -L -O -N -L -I -F -E .com, backslash moonshot. Get started on your longevity journey with Prolon today. Now back to the episode. Yeah, you know, one of the things that's important for people to realize is that we're doing this competition now because for the first time ever small teams can do what only the largest corporations and healthcare systems could do before.

56:28In fact, I think you can do more. Given the use of AI and what we'll see before the end of this competition, before 2030, is we'll see quantum chemistry and quantum computation coming online. Gene therapies, CRISPR, technology, gene writing, all kinds of things coming on. at exponential rates. And I think the biggest opportunity for impact on the planet is going to be for adding health onto people's life. Let's talk about one second, the definition of lifespan and health span. I think it's important for people to realize that you're in the same time. You're so right. Yeah. Yeah, go for it. So what's lifespan?

57:09So this is a really good point. This is a really, really good point. Okay, so lifespan, right? So this is, you know, a lot of people when we talk about this prize, they see only sort of the lifespan numbers. And lifespan is super important, right? It's how long you have lived. It's the total duration of your individual life. It's your chronology. Burst till death. How many birthday candles you have put on your cake? And it has really not a lot of connection necessarily to your health condition. So, birthday candles, whether or not you can actually count them or not. Yeah, whether you can blow them out even, see them.

57:43I know. Exactly right. So, health span is different. Okay, so health span is the period of life spent in good health. So, you know, classically we think about this is when you're free of like major life -threatening diseases or disability. So, it really, it emphasizes the quality of life rather than just the duration. So, again, we want to add life to your years. This is really the key component here. And you know, and one of the reasons this is such a key component because this is really where the gap is Peter, I know you're aware of this and I'm sure that our listeners, if you made it in this far, you probably know this.

58:24We talked about that longevity revolution at the beginning of the show. I'm just drawn a loop back. Did you know so in the US, right? We've gained 30 years in the last 100 years. We're living 30 years longer. Do you know what's helped been to the World Health Organization count something called the Health Adjusted Life Years. Do you know how long we've expanded that? No, no. And the last 20 years, zero. Right now there's a gap between our Health Adjusted Life Years and our lifespan of 12 years, meaning that we've extended life and we might have wiggled health a little bit, But if we actually quantify it, there are, it's a 12 -year period that people are living in poor health, low quality of life, poor function and disability.

59:14That's staggering. That's not the goal. That's not the goal. It's not the goal to have you slobbering in a wheelchair unconscious. That's right. How do you have the energy, the cognition, the mobility, the aesthetics, the immunity to enjoy those years of life? That's right. Traditional medicine has, yeah, traditional medicine has made us less dead. We want to make us more alive. I love that. The less dead express. You know, I want to talk about, you know, one more subject for folks here, which is, you know, people complain about extending life span or longevity and they bring up a number of things.

1:00:01And I went out to my Twitter verse to get people's objections. I normally I have a community of folks many of you here listening who love this and follow this with me. Again, I, you know, put out my book, Longevity, a practical playbook, which is available for free if you're listening on my DMandis .com backslash Longevity or you can go to Amazon on to get a hard copy. But the interesting list of things and it's going to run through them. The first is board. People say I'm going to be bored. I'm going to be bored if I lift you 100 or 120. And I'm like, really? So I think that's interesting. My answer to ways to engage in the world and hopefully boredom is the last thing you have to worry about.

1:01:03I don't know how you feel about that. No, I actually think that's completely right. And I'd have talked to others in the field is that we're going to have to come to terms with this. We are living longer and I think our current approach has actually left that feeling as that people don't know what to do with those added years. So I think that's where that's like, I'm going to be bored. Oh, I don't know what to do. Or they, you know, even with in medicine, there's this sort of palliative approach to care. And it's really, it's, we're looking for things that actually empower people, is you don't have to be bored.

1:01:36Maybe go back to school. Is there an opportunity for life? Yeah, I think. Is there engagement? There's so many things. Yeah. I think there's travel and education. and I think what happens is people can inflate being in pain and having low energy with those later years. And the hope is that they'll be increased vitality. Okay, so another thing is the sense of immortal dictators. I had this debate with Elon that people need to die in order to make room for new innovation. and if the CEOs and the leaders are still alive and living longer that we only have change when we have turnover and people die.

1:02:24And I call bullshit for that. I mean, you know, I listen, the head of Lockheed Martin and Boeing or General Motors in Thailand, I didn't have to die for SpaceX and for Tesla to come along. You just need better entrepreneurs and better technology. And I think we have revolution all the time. And we are going to have, without question, the societal checks and balances against evil dictators and tech for those who work well. Yeah, so I mean societal evil dictators, but I'll get clear. And so there's been a side conversation around this on the academic side around 10 where there's so many more new PhD candidates coming up and we can't do anything if nobody retires because of tenure.

1:03:19So there's all these fear, fear, fear, fear, fear. But instead, so we can either do two things. We can either not talk about it or we can talk about it and just sort of allow a place for engagement. Is this a potential risk? I'm with you, Peter. I certainly don't think so, but I also realize that I am an eternal optimist. But this is a great chance. This is why these prizes are so incredible. Is that they take some of these things that might be scaring people in the background about unintended consequences like the evil dictator syndrome or whatever that may be, which I also don't agree with. Or I'm going to be bored or any of these things.

1:03:59They allow us to have a public global conversation about them. We can talk about doing this prize. Bring them out, have pros and cons, come to a team summit, come to a biomarker summit. We're going to have a lot of opportunities and channels to communicate and talk about this. Is that we are going to have to talk about reskilling. We're going to have to talk about whether it's turnover, or just new opportunities for engagement. Like this is an opportunity that we get to have. And I think it's beautiful. The other side of tenure and able dictators is till death do us part in marriage. You know, it's too some marriage.

1:04:43Was it specifically designed to last for a hundred years? I don't know about that. So maybe we're going to have, as people live longer, we're going to have to have change, whether it's when you retire and social security and maybe marriage becomes a renewable contract and the tenure goes away. But, you know, interesting. Overpopulation, we spoke about the issues of overpopulation. I wouldn't hit on that again. But another is inequality. You know, is this simply for the wealthy you mentioned this? And that's not the objective, yeah? Yeah. No, it's not the objective. But again, this is one of those we talk about unintended consequences.

1:05:30This is the purpose of having a global prize rather than have a company or group of companies sort of do this their way. Is that we want companies to participate, be a part of a team, be part of the conversation. You know, I am, and I certainly, for me, the goal is not to, and again, it is not an awarding criteria, but it's part of a judge consideration as we talk about, we don't call it cost, we're talking about accessibility. right? Because even if you have a cheap drug, if it's not something that can be given and say, you know, in other sort of lower -emittal income countries that might not have access to the appropriate refrigeration or the blister packs aren't quite right in order to get, you know, people can use them or the dosing schedules are too complex, you know, so there's a lot of things that when we think about access that's really very important, one of those considerations is cost.

1:06:22But I think one of the key features when we think about cost -peaters, you said it sort of two ways, right? So there's the importance is that if we get these out there, the costs will eventually come down. The next thing is that if we actually can go about this the right way and that we can actually go forward and we can get an indication. And again, whether you're collaging the disease or not, that's not my dog fight, right? That's not mine. I let other people handle that. But the goal is still the same. Is that if we can get this through, whether as a disease or a non -disease indication, which the FDA is interested in driving forward, that makes health reimbursable.

1:07:02Right? And so that automatically is going to start bringing that cost back down so that we can talk about access and delivery. And if we can couple this with additional innovations and say, Peter, you and Ana, last month, We're at some really interesting conversations around, you know, decentralized medication, essential medication. So is this an opportunity that we can really drive change in that area? And I think one of the other key things is that when we're talking about function, we're automatically going to talk about improving the health and the lives of those who actually experience those declines perhaps earlier, either as accentuated or accelerated aging.

1:07:43And those are the people who really need it. You know, aging is essentially, it's the great equalizer. Everyone gets here eventually. Some of us might get here a little bit sooner. And if we make action now, and we actually can work on some of those access issues and work on the regulatory issues collectively, the idea is that we can actually create that level playing field and give innovation and innovative solutions to the populations who need them the most. This could be the great equalizer if we do it correctly and out in the open transparently and with a great global partnership. So there you have it, our health span XPRI is 101 million, actually it's 111 million if you include the bonus prize.

1:08:27That's great. Our mission is stimulate moonshot entrepreneurs. If you're not in the biotech or medical field, maybe you'll organize a team, go and find the smartest people you can pull together a team to compete for this. You know, we had some 6 ,000 teams pre -register for Elon's $100 million carbon exprise and then down to some 1 ,400 registered teams. By the way, I have to tell the side story here. Why is it $101 million, not $100 million prize? It was in a conversation with Chip Wilson who put up the first $25 million and then a $10 million FSHD bonus prize and said, huh, Elon's prize is $100 million.

1:09:18How about we make it larger? And it said, you want to kick in the next $1 million? He said, sure. And it became $101 million prize. I just want to again go to xprice .org, check out the xprice foundation, go to xprice .org, backslash, health span. You can get the guidelines there, you can register as a team, you can find out what else we're doing in the xprice world. For me, it's really moonshot heaven for moonshot entrepreneurs. Jamie, what else do I want to add here? Oh my gosh, all I want to say is, you know, come join us, right? So this is us, we're democratizing science, we're encouraging people to rethink about your relationship to aging and the community around you who is aging.

1:10:05And that, you know, all I want is for everyone to show up, knock on our doors, actually go on to our website. Again, that's xprice .org. Make sure you go on. They'll get that intent to compete. sign up your team. If you need help or access linking up to teams we're building that global community. Feel free to reach out. This is again this is a radically collaborative effort and I am so excited to have you join me on the journey. Pleasure. I want to thank Hevolution, our largest sponsor, Chip Wilson and solve FSHD and a myriad of individual sponsors who put in from a million to $10 million each for supporting this exprise for our advisors, our endpoints committee, the teams who have ready registered to compete.

1:10:59We have some amazing individuals top in their fields who are part of this competition, go and check it out. And Jamie, you and your team, you are playing all out on this and you're giving amazing, amazing team. Actually, I think you've got an all -female team, which is pretty amazing. Not intentional, but oh my gosh, we have an incredible, like a powerhouse team of women. So I'm joined. I should have given them a shout out way earlier. In addition to the incredible folks at X Prize, which has the most amazing support, prize design, advancement, partnerships, great teams. But my immediate team, I also have joined by a medical deputy, Dr.

1:11:42Laura Gets. I have a senior epidemiologist and data analyst and her name is Dr. Lauren Peer Point. And we have the amazing Delali, which I recommend anybody who needs information or contact. She's our prize manager. If anything gets done on this prize, she is our Get It Done Gal. And then of course our CEO Anusha Ansari who funded my first exprise back 23 Years ago then flew to the space station as a first private female astronaut and five years ago came back to bless us all as CEO of the exprise I service executive chairman, which means I Get to be her pain the ass and her partner And she was a self for me coming out from academia.

1:12:31She is my sheer. I just love her. Yeah, she wrote. All right. That said, the $101 million Hellspan XPRIZ out to change the world excited for everybody's going to compete and to add 20 healthy years on to my Hellspan. I'm looking forward to it. All right, everybody. Speaker, Peter, grateful for you. Thank you. Thank you, Jamie. Take care now. I want to take a moment to tell you about Abundance 360. My year -round leadership mastermind for people who want to go big, great wealth, and uplift humanity. It's singularity university's highest level program. We are a global community of entrepreneurs, CEOs, investors, philanthropists who have come together based upon a set of shared beliefs.

1:13:18I'm going to share with you a few of these core beliefs if they resonate with you, consider applying to the membership. We believe in the power of entrepreneurs to solve the world's biggest problems. Second, we believe it is possible to create wealth while at the same time uplifting humanity. Third, we believe that by the end of this decade, 2030, we'll be extending the healthy human lifespan by decades. Next we believe that the day before something is truly a breakthrough, it's a crazy idea, so embracing crazy ideas is critical to innovation. Next we believe that exponential technologies create abundance.

1:13:59And finally we believe that an entrepreneur's mindset is your greatest asset. If hearing these as you thinking that sounds like me and I want to be part of this community, then consider submitting your application to a360 .com. That's a360 .com. We let in about 50 new members every year in advance of our summit between March 17th and 21st. These spots sell out fast, so if you want to get in, consider applying early to increase your chance. A360 .com has everything you need to know. I hope you'll join me. It's an extraordinary group of entrepreneurs and we'd love to have you. Now back to our podcast.

1:14:57And Doug, here we have the Lemo Imu in its natural habitat, helping people customize their core insurance and save hundreds with Liberty Mutual. Fascinating. It's accompanied by his natural ally Doug. Uh, Lemoo? Is that guy with the binoculars watching us? Cut the camera. They see us. Only pay for what you need at LibertyMutual .com. Liberty Liberty Liberty Liberty Liberty Liberty Savings very underwritten by Liberty Mutual and Churns Company and affiliates excludes Massachusetts.